Acquired coagulation factor deficiency is a rare disorder that occurs in patients with drug reactions, malignancy and collagen diseases as well as during pregnancy. Most cases are caused by factor VIII inhibitors. We herein describe the case of a 61-year-old Japanese man with acquired factor V inhibitor who developed symptoms 11 days after lung surgery for empyema. The patient required mechanical ventilation to treat acute respiratory failure due to severe pulmonary hemorrhage. He responded poorly to steroid pulse therapy; however, treatment with rituximab was successful.
Introduction
Acquired coagulation factor deficiency is a rare bleeding disorder caused by the presence of coagulation factor inhibitors, with an estimated incidence of approximately one per million individuals per year (1) . The mortality rate of acquired hemophilia A is 10-20% (2). Treatment with steroid and rituximab therapy is recommended to suppress the titer of autoantibodies. Bypass therapy with activated factor VII is used in severe cases of hemorrhage in the brain, lungs and gastrointestinal tract (3) . To date, only a few cases of acquired deficiency of multiple coagulation factors associated with the presence of inhibitors have been reported (4) . We herein report the clinical course of a patient with acquired factor V inhibition who developed severe pulmonary hemorrhage 11 days after undergoing surgery for empyema. Steroid pulse therapy was ineffective, and the patient became critically ill with acute respiratory failure due to worsening pulmonary hemorrhage. Therefore, he was treated with rituximab. His laboratory data became normal six days after the initial treatment with rituximab, and he has remained free from relapse for at least one year.
Case Report
A 61-year-old man was admitted to our hospital for thoracoscopic pleural curettage surgery for the treatment of empyema. Ampicillin/sulbactam (ABPC/SBT) was administered after the procedure. Eleven days after surgery, he suddenly presented with dyspnea and hemoptysis. A physical examination showed pale-colored conjunctivae and petechiae in the oral cavity. The patient's lung sounds were coarse in the right chest. Ecchymosis was observed around the right elbow, with petechiae on both legs. A blood test demonstrated normocytic anemia. A blood coagulation study demonstrated prolongation of both the prothrombin time (PT) and activated partial thromboplastin time (APTT). As the patient had exhibited normal PT and APTT values before surgery, we concluded that the coagulopathy was acquired. A chest X-ray showed a massive infiltrative shadow in the right pulmonary lobe, suggesting alveolar hemorrhage (Fig. 1) .
The presence of acquired inhibitors of coagulation factors was suspected, and a cross-mixing test using serum from the patient and a healthy volunteer was performed. The PT and APTT curves were upward convex in shape (Fig. 2) , thus indicating the presence of coagulation factor inhibitors. Tests for lupus anticoagulant and cardiolipin antibodies were both negative. Serum protein electrophoresis did not show any abnormal patterns. At that time, we received the laboratory data regarding coagulation factors V and X and their inhibitors, although data for other coagulation factors were lacking (Table) . The activity of factor V and X was low as <3% and 5%, respectively. In addition, tests for inhibitors against factor V and X were positive, with titers of 83 BU/mL and 2 BU/mL, respectively. Therefore, we initially diagnosed the patient with acquired deficiency of coagulation factors V and X. However, the final diagnosis was the presence of an acquired factor V inhibitor, as described below.
The patient was treated with steroid pulse therapy for three days followed by 1 mg/kg/day of prednisolone (Fig. 3) . However, the response to therapy was poor. The patient developed acute respiratory failure due to worsening pulmonary hemorrhage; therefore, mechanical ventilation was started on Day 8. In order to treat the acquired coagulopathy and prevent death due to rapid progression of the pulmonary hemorrhage, the patient received rituximab therapy on Day 14. As the use of rituximab for acquired coagulation factor deficiency is an off-label treatment in Japan, we obtained informed consent from the patient and his family. Six days after the initiation of treatment with rituximab, the patient's respiratory status and coagulopathy dramatically improved (Fig. 3) . Following the patient's recovery, we obtained all laboratory data, which indicated a significant decrease in the activity of multiple coagulation factors and the presence of multiple inhibitors (Table) . In particular, the factor V inhibitor level was as high as 83 BU/mL. As the titers of other inhibitors were not as high as that of anti-factor V ( Table) , we considered that some of the inhibitors were nonspecific, as a high titer of factor V inhibitor can interfere with the assay of other coagulation factors. A final diagnosis of the presence of acquired factor V inhibitor was therefore made.
Discussion
Acquired coagulation deficiency due to the presence of inhibitors is rare and sometimes life-threatening. Despite the fact that numerous cases of factor VIII inhibitor and more than 100 cases of factor V inhibitor have been reported (5) , there are only a few case reports of deficiency of coagulation factors due to the presence of other inhibitors (4) . Interestingly, we detected multiple inhibitors for a broad range of coagulation factors (Table) . We acknowledge the possibility of false-positive results for coagulation factor inhibitors (6,7), as the level of factor V inhibitor was 83 BU/mL, which was much higher than that of the other inhibitors (Table). It has been previously reported that some factor VIII inhibitors cross-react with other coagulation factors (8) .
Surgery, drugs, malignancy, child birth and autoimmune disorders are known to be possible causes of the presence of acquired coagulation factor inhibitors (9) . In the present case, bacterial infection, surgery and the use of antibiotic therapy may have contributed to the onset of this disease. Although there are several reports of acquired factor V deficiencies caused by the administration of bovine thrombin during surgery to stop bleeding (5, 10), this treatment was not used in the present case during surgery for empyema. Antibiotics, especially β-lactams, are well-known causes of acquired hemophilia (11) , and our patient received ABPC/ SBT after surgery. However, it remains to be elucidated how factor V inhibitor was induced in this case.
Rituximab is an anti-CD20 antibody that is used to treat B cell malignancies. Recent studies have demonstrated that rituximab is also effective for a number of autoantibodymediated diseases, including thrombotic thrombocytopenic purpura (12) , autoimmune hemolytic anemia (13), immune thrombocytopenia (14) and the presence of acquired factor VIII antibodies (15) . Rituximab has been used in three patients with severe and symptomatic disease due to the presence of acquired factor V inhibitor (5) . In the present case, the patient became critically ill due to the progression of pulmonary hemorrhage following treatment with steroid pulse therapy. He was successfully treated with rituximab, and has remained in complete remission for at least one year. As the number of cases of acquired coagulation factor deficiency is low, it is therefore necessary to evaluate the efficacy, safety and optimal dosage of rituximab in such patients in future clinical trials.
The authors state that they have no Conflict of Interest (COI).

